FLORIS ENGELHARDT's career in nucleic acids began with an undergraduate thesis in 2013 on DNA binding protein kinetics, which established a persisting love for the DNA field.Her PhD involved a study of DNA origami with Hendrik Dietz, developing three-dimensional nanostructures using DNA.This, in combination with her postdoctoral studies at MIT, sparked a vision that led to the establishing of Kano Therapeutics, a biotech startup enabling the correction of gene-length stretches of DNA using circular single-stranded DNA.
No takes yet. Share an insight, caveat, or question.
F. R. Engelhardt (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: